Publications by authors named "Sackmann F"
Article Synopsis
- * Two specific DAMPs, HMGB1 and S100A8/A9, were found to be elevated in MF patients and linked to higher systemic inflammation and adverse clinical outcomes, such as anemia and lower survival rates.
- * Monocytes in MF patients are hyperactivated and contribute to increased levels of S100A8/A9, while also showing a strong inflammatory response through Toll-like receptors TLR4 and TLR2, suggesting that DAMPs
Myelofibrosis (MF) is a clonal hematopoietic stem cell disorder classified among chronic myeloproliferative neoplasms, characterized by exacerbated myeloid and megakaryocytic proliferation and bone marrow fibrosis. It is induced by driver (//) and high molecular risk mutations coupled to a sustained inflammatory state that contributes to disease pathogenesis. Patient outcome is determined by stratification into risk groups and refinement of current prognostic systems may help individualize treatment decisions.
View Article and Find Full Text PDFThe role of Ann Arbor staging in determining treatment intensity after achieving a negative positron emission tomography (PET) has not been established in classical Hodgkin lymphoma (cHL). Patients with stage I-IV cHL, received three cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and an interim PET scan (PET3). PET3-negative patients received no further therapy.
View Article and Find Full Text PDFArticle Synopsis
- Myelofibrosis (MF) is a serious blood cancer that leads to low blood cell counts and various symptoms, especially in patients with low platelet levels (thrombocytopenia).
- A study examined the quality of life and symptom severity in 418 MF patients, showing that those with thrombocytopenia had significantly worse symptoms and higher total symptom scores compared to those without.
- Patients with severe thrombocytopenia faced even higher risks of anemia and other complications, highlighting the need for improved treatment options for these individuals.
Article Synopsis
- - The study investigates how gender affects the symptoms and complications of myeloproliferative neoplasms (MPNs), which include polycythemia vera, essential thrombocythemia, and myelofibrosis, involving 2,006 patients.
- - Findings reveal that females are more likely to experience severe and frequent symptoms compared to males, despite similar quality of life scores, with women particularly reporting worse abdominal and microvascular symptoms.
- - Males, on the other hand, are more likely to have polycythemia vera and experience complications such as thrombocytopenia and greater red blood cell transfusion requirements, along with shorter disease duration.
Article Synopsis
- Polycythemia vera (PV) is a condition linked to serious health issues and unpleasant symptoms, and JAK inhibitor therapy has shown promise for patients who have previously used hydroxyurea (HU) and experience symptoms like splenomegaly.
- A study evaluated 1,334 PV patients to investigate how previous HU use, phlebotomy needs, and splenomegaly contribute to symptom severity.
- Findings revealed that each of these factors is associated with a significant symptom burden, and having more than one feature increases the severity of symptoms, highlighting that patients with any of these issues experience considerable discomfort.
Symptom burden in myeloproliferative neoplasms (MPNs) is heterogeneous even among patients within the same MPN diagnosis. Using cluster analysis from prospectively gathered symptom burden data in 1470 international patients with essential thrombocythemia (ET), polycythemia vera (PV), or myelofibrosis (MF), we assessed for the presence of clusters and relationship to disease features and prognosis. In MF (4 clusters identified), clusters significantly differed by Dynamic International Prognostic Scoring System (DIPSS) risk (P < .
View Article and Find Full Text PDFArticle Synopsis
- The study focused on developing an abbreviated symptom score (MPN-SAF TSS) to assess and track the most relevant symptoms experienced by patients with myeloproliferative neoplasms (MPNs), aiming to improve treatment outcomes.
- Analysis included 1,408 MPN patients and revealed significant differences in symptom scores across different MPN subtypes, with a strong correlation to overall quality of life and internal consistency.
- The MPN-SAF TSS showed potential as a reliable tool for measuring symptom burden in MPN patients, making it valuable for evaluating treatment responses in future studies.
This multicenter, open-label study evaluated the efficacy and safety of decitabine in patients from Argentina and South Korea with myelodysplastic syndromes or chronic myelomonocytic leukemia. Of 106 patients who received decitabine 20 mg/m(2) intravenously over 1 h once daily for 5 days in 4-week cycles, 99 patients were evaluable after receiving at least two cycles. The overall improvement rate was 35% (19% complete response +4% marrow complete response +4% partial response +8% hematologic improvement).
View Article and Find Full Text PDFObjective: To determine the prevalence of JAK2 V617F mutation and its clinical correlation in patients with chronic myeloproliferative disorders (CMD): polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF).
Materials And Methods: Detection of JAK2 V617F mutation by allele specific-PCR.
Results: One hundred and three patients with CMD were included in the study.
A retrospective evaluation of 285 patients with monoclonal gammopathy of undetermined significance was performed to identify variables associated with progression, actuarial progression free survival (PFS) and overall survival (OS). Three variables, level of uninvolved immunoglobulins (HR 4.98, CI95% 2 -12.
View Article and Find Full Text PDF